Ozmosi | Acupuncture Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

Acupuncture

Alternative Names: Acupuncture
Clinical Status: Inactive
Latest Update: 2026-01-14
Latest Update Note: Clinical Trial Update

Product Description

Acupuncture in the treatment of acute toxicity during and after head and neck cancer radiotherapy; In this interim analysis, acupuncture leads to lower pain andfaster disappearance of skin and mucosal toxicity after (chemo)radiotherapy of head and neck cancer. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/32597419/)

Mechanisms of Action: No Mechanism

Novel Mechanism: No

Modality: Unknown

Route of Administration: N/A

FDA Designation: *

Approval Status: Not Approved

Approved Countries: Australia

Approved Indications: None

Known Adverse Events: None

Company: Zhejiang University
Company Location: Asia Pacific
Company CEO:
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Acupuncture

Countries in Clinic: Taiwan, United States

Active Clinical Trial Count: 2

Recent & Upcoming Milestones

Highest Development Phases

Phase 2: Breast Cancer|Breast Diseases|Dyslipidemia|Obesity|Peripheral Nervous System Diseases

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT05458284

NCT05458284

P2

Active, not recruiting

Peripheral Nervous System Diseases|Breast Diseases|Breast Cancer

2026-07-01

2025-08-29

Primary Completion Date|Primary Endpoints

NCT06703788

MOHW113-CMAP-M-113-000003-B

P2

Recruiting

Dyslipidemia|Obesity

2025-06-01

2024-11-27

Primary Endpoints|Treatments